Genzyme Successfully Meets First Milestones of FDA Consent Decree

All Filling and Finishing for U.S. Market Transferred Out of Allston Plant

30-Nov-2010 - USA

Genzyme Corporation announced that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree. All fill/finish activities for Cerezyme® (imiglucerase for injection), Myozyme® (alglucosidase alfa), Fabrazyme® (agalsidase beta) and Thyrogen® (thyrotropin alfa for injection) for the U.S. market now take place at Genzyme’s Waterford, Ireland plant, and at an external contract manufacturer. With this move, all previous restrictions on the marketing and distribution of Thyrogen within the United States have been lifted.

All remaining fill/finish activities in Allston for products sold outside of the United States must be ended by August 31, 2011. Genzyme is working closely with regulatory authorities globally to achieve this goal.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances